No profile data available.
Matinas BioPharma Holdings, Inc. (MTNB) is a healthcare company in the additional infection treatment pharmaceuticals industry, based in Bedminster, United States, with about 2 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$10.96 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $2.81 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Matinas BioPharma reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$2.81 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional infection treatment pharmaceuticals) include Daré Bioscience, Inc. (DARE), Pulmatrix, Inc. (PULM), 60 Degrees Pharmaceuticals, Inc. (SXTP).